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Abstract
Background: Chondrosarcomas are the second most frequent primary malignant type of bone tumor. No effective systemic
treatment has been identified in advanced or adjuvant phases for chondrosarcoma. The aim of the present study was to
determine the antitumor effects of doxorubicin and everolimus, an mTOR inhibitor on chondrosarcoma progression.
Methods and Findings: Doxorubin and/or everolimus were tested in vivo as single agent or in combination in the rat
orthotopic Schwarm chondrosarcoma model, in macroscopic phase, as well as with microscopic residual disease. Response
to everolimus and/or doxorubicin was evaluated using chondrosarcoma volume evolution (MRI). Histological response was
evaluated with % of tumor necrosis, tumor proliferation index, metabolism quantification analysis between the treated and
control groups. Statistical analyses were performed using chi square, Fishers exact test. Doxorubicin single agent has no
effect of tumor growth as compared to no treatment; conversely, everolimus single agent significantly inhibited tumor
progression in macroscopic tumors with no synergistic additive effect with doxorubicin. Everolimus inhibited
chondrosarcoma proliferation as evaluated by Ki67 expression did not induce the apoptosis of tumor cells; everolimus
reduced Glut1 and 4EBP1 expression. Importantly when given in rats with microscopic residual diseases, in a pseudo
neoadjuvant setting, following R1 resection of the implanted tumor, everolimus significantly delayed or prevented tumor
recurrence.
Conclusions: MTOR inhibitor everolimus blocks cell proliferation, Glut1 expression and HIF1a expression, and prevents in
vivo chondrosarcoma tumor progression in both macroscopic and in adjuvant phase post R1 resection. Taken together, our
preclinical data indicate that mTOR inhibitor may be effective as a single agent in treating chondrosarcoma patients. A
clinical trial evaluating mTOr inhibitor as neo-adjuvant and adjuvant therapy in chondrosarcoma patients is being
constructed.
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Introduction
Chondrosarcomas constitute a heterogeneous group of neo-
plasms accounting for 20% of bone malignancies, that have in
common the production of cartilage-like matrix by the tumor cells
[1]. Clinical management of these second most common type of
skeletal malignancies after osteosarcoma has remained largely
unchanged over the last 3 decades [2]. Because of their
extracellular matrix, low percentage of dividing cells, and poor
vascularity, chondrogenic tumors are relatively chemo- and
radiotherapy resistant [2,3]. Chemotherapy and radiation have
not been tested for efficacy, but in clinical routine they are not
considered as active for the treatment of this disease and surgery
still prevails as the primary treatment modality of this tumor [2,3].
The 10-year survival rate of chondrosarcoma being unchanged
over the past 40 years and ranging from 29–83% [1,4] depending
on the chondrosarcoma subtype and grade. Improving chondro-
sarcoma clinical management is therefore a challenging problem
and novel therapeutic approaches are needed.
The idea of targeting mTOR as anticancer strategy emerged
less than a decade ago and became rapidly a focus for cancer
therapeutic developments [5,6]. MTOR is a ubiquitously
expressed serine/threonine kinase that affects a number of cellular
functions, from protein synthesis to cell proliferation. MTOR is
also a point of convergence in many signalling pathways that
respond to growth factors and stress/energetic status [7,8].
MTOR integrates all these signals and acts by modulating the
phosphorylation of p70S6 kinase (p70S6K/S6K1) and 4E binding
protein 1 (4E-BP1) leading to protein synthesis and cell cycle
progression (G1 to S phase transition) [9]. MTOR is a central
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upon which tumor cells depend and there are growing data
indicating that many cancers present alteration upstream and
downstream of mTOR leading to this pathway abnormal
activation [5,10]. Thus mTOR represents a potential therapeutic
target and efforts have been made to develop inhibitors specific for
this protein [6,11].
Rapamycin (sirolimus) and its analogues temsirolimus and
everolimus have shown specific mTOR inhibition and anticancer
activities in preclinical trials [12–14]. Previous studies have shown
that specific mTOR inhibitor used as monotherapy or in
combination with other agents had an antitumoral effect in solid
or haematological malignancies [15,16]. Pivotal clinical trials with
mTOR inhibitors are ongoing in solid tumors including neuro-
endocrine tumors, breast cancer, gastric cancer [6]. Recently a
case report of a response to an association of rapamycin and
cyclophosphamide in a case of myxoid chondrosarcoma was
published pointing out a possible role of this approach in clinical
setting [17].
Based on these data and on studies showing additive effects of
mTOR inhibitor with chemotherapy [14,15,18,19], the antitumor
effect of a combination of chemotherapy and/or everolimus, an
mTOR inhibitor was tested in a preclinical rat chondrosarcoma
model. We present here the results of this study.
Methods
Care of and procedures for animals were performed according
to institutional and national guidelines. The study was approved
by the Cermep ethics committee (Cermep COMEX) and
registered under the ID: DUTOUR_Chondro01/03. Animals
were housed and experiments were carried out at Cermep a
structure approved for housing and small animal experimentations
(agreement number: A 69 383 05 01). For each tumor model,
three experiments were carried out.
Animals were anesthetized throughout all surgical and imaging
procedures with isoflurane/oxygen (2.5%/2.5%, v/v) (Minerve,
Esternay, France).
Rat chondrosarcoma model.
Primary Chondrosarcoma Model
The transplantable orthotopic rat chondrosarcoma has been
described [20]. This model is a grade II chondrosarcoma with
mild cellular atypia that mimics its human counterpart in terms of
aggressiveness and chemoresistance phenotype. Tumors were
grafted on 25-days-old Sprague–Dawley rats (Charles River
Laboratories, L’Arbresle, France). Briefly, tumor fragments
(10 mm
3) were transplanted on the right posterior tibia of the
rats after periostal abrasion. At day 12 after tumor transplantation,
animals underwent a first MRI and were randomly divided into
the following groups: i) Control (saline; n=7); ii) doxorubicin
(1 mg/kg; n=7) (Doxorubicin; Baxter, Deerfield IL, USA); iii)
everolimus (1 mg/kg; n=7) (CerticanH, Novartis; Rueil-Malmai-
son, France); iv) everolimus + doxorubicin (1 mg/kg each; n=7).
Doxorubicin is an agent commonly used in the treatment of
musculoskeletal sarcoma and was therefore chosen as ‘‘reference
treatment’’ in our study. Treatment was administered IP twice a
week starting day 12 and for 3 weeks, animals were imaged every
10 days throughout treatment. Previous studies conducted in our
group showed that the dose of 1 mg/kg of doxorubicin and
everolimus is well tolerated and effective in the rat chondrosar-
coma model. Increasing the doses (for each compound) accrued
little antitumor activity. Thus 1 mg/kg of everolimus and
doxorubicin appeared to be the optimal dose in our sarcoma
model. All animals were euthanized if tumor were too bulky or if
any signs of distress were observed.
Model of Local Tumor Recurrence
Primary chondrosarcoma were obtained as described in the
previous paragraph. When the tumors reached a volume of
approximately 500 mm
3 (and considered progressive tumors), the
animals underwent an intralesional curettage [20]. One day after
intralesional surgery, treatment was initiated. Rats were treated
with everolimus alone at the dose of 1 mg/kg twice a week, or with
doxorubicin alone (1 mg/kg) twice a week or by saline (as vehicle)
for 3 weeks or till tumors reached the size of 2 cm in the largest
diameter. Rats were imaged throughout treatment by MRI. All
animals were euthanized if tumor were too bulky or if any signs of
distress were observed. At the conclusion of the study, tumors were
dissected, weighed, and processed for further analysis.
Tumor Growth Assessment
Two perpendicular diameters were measured using a caliper
twice a week and tumor volume was estimated using the formula
V=0.5*0.5*a*b
2, where a and b were respectively, the largest and
smallest perpendicular tumor diameters.
Chondrosarcoma-bearing rats underwent MRI examinations
on days 0, 10 and 20 after initiation of treatment.
MRI acquisition was performed 15 min after intravenous
administration of gadolinium. MRI acquisitions were performed
on a Bruker 7T Biospec system (Bruker, Ettlingen, Germany)
equipped with 400 mT/m gradient set, using an emission/
reception body coil (o.d.=112 mm and i.d.=72 mm). Then,
T2-weighted contrast images were acquired in the axial and
coronal plane based on a fat suppressed (FS) rapid acquisition with
relaxation enhanced (RARE) sequence with the following param-
eters: repetition time (TR) 3625,2 ms, echo time (TE) 60 ms,
RARE factor =8 and 3 min scan time. T1-weighted contrast
images were acquired in the axial and coronal plane based on a fat
suppressed (FS) spin echo (MSME) sequence with the following
parameters: repetition time (TR) 584,4 ms, echo time (TE)
10,7 ms and 4 min scan time. For both sequences, a total of 25
slices (slice thickness 1 mm) was acquired with a field of view
(FOV) of 767c m
2, matrix 2566192, resulting in an in-plane
resolution 2736365 mm
2.
Western Blotting
Immunoblotting was done to confirm everolimus inhibitor
activity and the upstream and downstream consequences of
mTOR inhibition. Tumor samples were pulverized under liquid
N2, and extracted as described previously. Immunoblotting
procedures have been previously reported. All proteins were
detected, after dosing, by resolving proteins on Criterion Mini
Protean 4–15% SDS-PAGE (Bio-Rad Laboratories, Marne La
Coquette, France) and blotted onto nitrocellulose membrane. The
following primary antibodies were used: anti-phospho-AKT
(S473; 1:1,000), anti-phospho-S6K (1:1,000), anti- 4EBP1
(1:1,000) anti-phospho-mTOR (1:1,000); anti- AKT (S473;
1:1,000), anti- S6K (1:1,000; Inc.), anti-mTOR (1:1,000). All were
from Cell Signaling Technology (Danvers MA, USA). Immuno-
reactive bands were visualized by using ECL Plus (GE Healthcare,
Orsay, France) and Biomax XAR film (Kodak) after incubation
with the horseradish peroxidase–conjugated secondary antibody
(1:5,000; Millipore; Molsheim; France). The ratio of phosphory-
lated to total signals was quantified unsing ImageJ software
(http://rsbweb.nih.gov/ij/).
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At the endpoint of study, histologic characterization and
immunohistologic analyses were performed on tumors from
representative animals of all groups. Tumors samples were fixed
in formalin solution embedded in paraffin and cut at a thickness of
5 mm for Ki67 and Glut-1 staining, For phospho-4EBP1 and
phospho-Akt staining, sections were embedded in OCT, frozen
and cut at a thickness of 5–6 mm. For immunostaining the
following primary antibodies were used: anti Ki-67 (1:50 Dako,
Trappes, France), anti-phospho-4EBP1 (1:400; Cell Signaling
technology), anti-phospho-Akt (1:400; Cell Signaling technology),
anti-Glut-1 (1:100; Abcam; Cambridge, MA USA). Detection of
Ki67 and Glut-1 immunostaining were performed using Vectas-
tain ABC Kit (Vector Laboratories, Burlingame, CA USA)
according to manufacturer’s instructions, followed by counter-
staining using hematoxylin (Sigma-Aldrich). Phospho-Akt and
phospho-4EBP1 were visualized using Texas Red-conjugated anti-
mouse secondary antibody (Vector Laboratories).
For quantitative assessment of Ki67 staining, a total of 200
tumor cells were evaluated per slide (in fields showing the highest
cell density (periphery of the tumor)) within an examination area of
0.196 mm
2. Glucose transporter 1 (Glut-1) staining was graded as
positive or negative. Cases were considered negative when less
than 10% of cells showed Glut-1 staining and positive when 10%
or more of tumor cells showed Glut-1 staining. Variations in
staining intensity of the cells were scored, and the following criteria
were used: +, weak but unequivocal staining in some cells; ++,
staining of moderate intensity; and +++, strong or intense staining.
All IHC slides were interpreted by two independent observers, one
being a qualified pathologist with no knowledge of the clinico-
pathologic variables evaluated in the specimens.
Quantitative Real-time PCR
Total RNA was extracted from representative tumors from all
groups using Rneasy Mini Plus Kit (Qiagen, Courtaboeuf France)
according to the manufacturer’s instructions. First-strand cDNAs
were generated in reverse transcriptase reactions containing 1 mg
total RNA and Quantitect Reverse Transcription kit (Qiagen).
Gene expression of rat HIF1a, GLUT-1 and HPRT was
quantified on a Applied thermocycler (Applied 7000) using
QuantiFast SybrGreen PCR kit and Quantitect primers (Qiagen).
For RT-PCR singleplex reactions, a final volume of 25 mL per
2.5 mL cDNA were diluted in RNase-free water,12 mL Quantifast
Master Mix, and 2.5 mL of primers. Amplification conditions were
set up to 5 min at 95uC followed by 40 PCR cycles (10 s at 95uC,
30 s at 60uC). The quantity of HIF1a and GLUT-1 cDNA
detected in each reaction was normalized to HPRT and expressed
as a ratio of sample cDNA to HPRT cDNA.
Statistical Analysis
Data points are given as mean values 6 standard deviation.
Results were compared by the nonparametric Mann–Whitney U
test, due to sample size. A p-value ,0.05 was considered
statistically significant.
Results
Everolimus Blocks chondrosarcoma Progression
To determine whether the combination of everolimus and
doxorubicin is therapeutically useful we examined the antitumor
activity of the individual agents and the combination of everolimus
with doxorubicin in the established orthotopic chondrosarcoma
model (Table 1 and Figure 1A). In these setting, data presented are
one experiment representative of three experiments. There was no
significant differences in tumor progression and mean tumor
volumes among the doxorubicin treated group and the control
group: at day 21 the mean tumor volume in the doxorubicin
treated group was 2130 mm3 (+/2330 mm3) and 2165 mm3 (+/
2370 mm3) in the control group (p.0.05). In contrast, everolimus
used as single therapy yielded an inhibition of tumor progression
but with no volumetric tumor regression (Table 1 and Figure 1).
Significant (p=0.001 at day 21) differences in average tumor size
were observed starting day 10 after initiation the treatment
between the everolimus treated groups and the control group, and
from day 14 between the everolimus and doxorubicin-treated
groups (Figure 1B; p=0.02 at day 21). Figure 1C showed a
representative MRI of tumor progression in the different groups:
the time to reach a relative tumor volume of 10 times the initial
tumor volume (T10) was 14 days in the control group, 16 days in
the doxorubicin group. Tumors in the everolimus treated group
did not reach this 10-fold value (Figure 1A). Everolimus resulted in
an approximately 55% inhibition of tumor growth at day 21
compared to either control or doxorubicin groups (Table 1;
p,0.05).
Lower Activity of the Combination Doxorubicin/
everolimus
The combination of doxorubicin with everolimus had lower
therapeutic efficiency than everolimus used alone (p=0.08) and
showed an intermediate additive effect in comparison to doxoru-
bicin (p=0.1) (Table 1 and Figure 1A). Median tumor burden
measured after three weeks of treatment was 1500 mm
3 (+/2272)
in the combination treated group versus 1140 mm
3 (+/2180) in
everolimus-treated rats. The time to achieve the 10-fold initial
tumor volume was 17 days in the combination group, vs. 16 days
in the doxorubicin treated group. Therefore, the slight tumor
growth delay observed in this group was due to everolimus activity,
indicating the antagonistic effect of the combination in vivo. This
lack of synergism between everolimus and doxorubicin was also
found in vitro in cell proliferation assay. In vitro everolimus by itself
had no antiproliferative effect on chondrosarcoma and osteosar-
coma cell lines (Figure S1) even at the concentration of 1 mM
whereas doxorubicin showed a potent antiproliferative effect on
both cell lines with an IC 50 of 0.1 mM (Figure S1) These data
were not surprising given the mechanism of action of everolimus
which is not a cytotoxic agent as opposed to doxorubicin. The
addition of everolimus to doxorubicin did not improve the in vitro
antiproliferative activity of the latter. More studies are ongoing to
understand the somewhat antagonistic effect of these two drugs.
MTOR Inhibition Caused Changes in Tumor Cells
Metabolism and Proliferation
After three weeks of treatment, no induction of apoptosis or
increase in tumor necrosis was observed histologically in either
treated groups (Figure2A).A reduction ofcell proliferation rate was
observed in everolimus treated tumors using Ki67 labeling.
(Figure 2A and Figure 2B). At the end of the experiment, 30% of
tumor cells showed a positive Ki67 staining in the everolimus-
treated tumors, 45% in doxorubicin treated tumors and 49% in
control group (Figure 2B). The difference in Ki67 positive cells
observed between the control or the doxorubicin-treated group and
everolimus treated groups were significant (p,0.01 in both cases)
whereas only marginal difference seen between the control and
doxorubicin treated group was not significant (p=0.054).
Using immunohistochemistry and RT qPCR, we evaluated the
expression of the glucose transporter Glut-1. Interestingly a
markedly decreased expression of Glut-1 was observed in the
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decrease of this marker was observed in the doxorubicin- treated
group (Figure 2A and Figure 2B). Glut-1 expression was
moderate and observed in 46% of tumor cells in the control
group, while it was of low intensity and in 40% of tumor cells in
the doxorubicin group (Figure 2). In the everolimus treated
tumors, 32% of tumor cells expressed the glucose transporter at a
weak level: this percentage was similar in tumors treated with the
Table 1. Summary statistics of tumor evolution for each treated group.
Control Group
(n=7)
Doxorubicin-treated
Group (n=7)
Everolimus-treated
Group (n=7)
Combination (everol+
doxor.) Group (n=7)
Mean tumor vol (mm3) D1 189 (+/242) 215 (+/233) 229 (+/257) 231 (+/248)
Mean tumor vol (mm3) D21 2165 (+/2370)* 2130 (+/2330)** 1139 (+/2180)* ** 1501 (+/2272)
Relative mean tumor volume D21 11.5 9.9 5 6.5
Tumor inhibition rate - 13.8 56.7 43.4
*; **significant differences between tumor volumes (p,0.05).
doi:10.1371/journal.pone.0032458.t001
Figure 1. Response of established chondrosarcoma model to each treatment. A, Mean tumor volume evolution between day 1 and day 21
(fold expansion are expressed beside each group). B:Time course of mean tumor volume (expressed in fold expansion compared to day 1). The results
indicated that everolimus as single agent significantly (p,0.01) slowed down chondrosarcoma progression; the combination of doxorubicin to
everolimus showed an additive effect in comparison to doxorubicin alone, but was less efficient than everolimus alone. C: Longitudinal growth of
tumor of one rat from each group monitored by MRI.
doi:10.1371/journal.pone.0032458.g001
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on the expression of glucose transporter Glut 1 was also seen at
the molecular level. RT qPCR showed a decrease in the
expression of GLUT-1 mRNA in the everolimus treated groups
whereas no variation in the GLUT-1 mRNA level was found in
the doxorubicin treated one. (Figure 2C).
The slight decrease in HIF1a expression (Figure 3) suggests that
the decreased Glut-1 expression is not due to changes in oxygen
levelsortumorhypoxia.ThedecreasedGlut-1expressionseenafter
treatment by everolimus alone, together with a less important
decrease in Glut-1 expression observed in the doxorubicin/ever-
olimus treated group and the absence of changes of Glut-1
expression in the doxorubicin group points to a metabolism
inhibitor effect linked to mTOR inhibition (Figure 2 and Figure 3).
ThecorrelationseenbetweenKi67andGlut1stainingsuggeststhat
everolimus inhibits chondrosarcoma progression mainly by inhib-
iting cell proliferation and down regulating tumor metabolism.
Everolimus Blocked mTOR Pathway with no Akt
Feedback Loop
Western blot combined with immunohistological analyses
showed a strong expression of phospho-Akt, phospho-mTOR,
and phospho-p70S6K in the orthotopic chondrosarcoma model
(Figure 4A–C), indicating that the mTOR signaling pathway is
activated in chondrosarcoma. We evaluated the effects of the
different treatments on mTOR pathway targets by immunohisto-
chemical staining and western blotting.
Doxorubicin alone did not decrease mTOR and mTOR
effectors activation levels No significant changes in p70S6K1
and 4EBP1 phosphorylation were observed in this group of tumors
(Figure 4A–B). The phosphorylated/total protein ratios of mTOR
effectors p70S6K1 and 4EBP1 were respectively of 48.6% and
57.3% in doxorubicin treated group versus 53.6% and 62.8% in
the control group. In contrast, treatment with everolimus resulted
in a significant inhibition (p,0.05) of p70S6K1 and 4EBP1
phosphorylation (ratio of phosphorylated form respectively 40.9%
and 32.9%) (Figure 4A–B) confirming the inhibition of down-
stream signaling of mTOR. Western blot analysis of total proteins
from the combination doxorubicin/everolimus treated tumors
showed that this treatment inhibits mTOR, p70S6K1 and 4EBP1
phosphorylation but to a lesser level than everolimus alone.
Everolimus alone did not led to an increase in Akt phosphorylation
in the chondrosarcoma model as seen by western blotting and
immunofluorescent stainings (Figure 4); in contrast an increase in
Akt phosphorylation could be seen by western blot in the
doxorubicin treated group (77.4% of Akt was phosphorylated in
these tumors) in comparison to the control one where 68% of Akt
was in its activated form in the control group. These data were
Figure 2. Everolimus inhibits tumor cell proliferation and glucose metabolism. A, Tumor cell proliferative rate (Ki67+ cells) and glucose
metabolism were significantly decreased after everolimus treatment. Tumors were harvested, fixed and stained by HPS, anti-Ki67 or anti-Glut-1
antibody to respectively show tumor proliferative fraction and glucose metabolism. B : Summary of Ki67 and Glut-1 expression for each treatment
group.Ctrl: control group, Dox: doxorubicin-treated group; Everol: everolimus-treated group; combi: everolimus + doxorubicin combination-treated
group. C: histogram showing Glut-1 mRNA expression after each treatment. Glut-1 mRNA induction was unchanged in response to doxorubicin and
decreased after everolimus treatment.
doi:10.1371/journal.pone.0032458.g002
Figure 3. Everolimus did not affect the expression of the hypoxia key regulator HIF1a. RT-qPCR detection of HIF1a mRNA. HIF1a mRNA
levels were expressed as a ratio of the corresponding HPRT mRNA level. Results indicate that everolimus induced a slight decrease (P=0,05) in
expression of HIF1a.
doi:10.1371/journal.pone.0032458.g003
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phospho-p70S6K1 was observed after treatment with everolimus showing the inhibition of mTOR pathway. Such a decrease was not obtained in the
Doxorubicin treated tumors. The expression of ph-Akt was not altered by treatment. B: inhibition of mTOR and its downststream effectors activation
after everolimus treatment was confirmed by a decrease of the ratio phosphorylated/total proteins (mTOR 4EBP1, p70S6K1, Akt). C,
immunofluorescent staining of ph-4EBP1 and ph-Akt confirmed the Western blot analysis. A strong decrease in ph-4EBP1 staining was seen in
tumors from the everolimus treated groups (either as single agent or combination treatment). Neither of the treatments induced changes in the
expression of ph-Akt.
doi:10.1371/journal.pone.0032458.g004
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cin alone (Figure 4). In this model and these conditions, everolimus
did not activate the feedback TORC2 loop on Akt activation: the
feedback was activated in response to doxorubicin and to a lesser
extent to the combination doxorubicin/everolimus (Figure 4).
HIF1a is a key element in tumor hypoxia and is overexpressed
in chondrosarcoma. This element is partly under the dependance
of mTOR signaling. The capacity of everolimus to downregulate
HIF1a expression was then tested. RT-PCRq established a slight
decrease in HIF1a expression in tumors receiving everolimus as
single agent or combined to doxorubicin whereas the chemother-
apy alone did not induced changes in HIF1 expression (Figure 3)
(from 1.12 to 1.08; P.0.05).
Adjuvant Everolimus Delays Chondrosarcoma Recurrence
We explored everolimus in an ‘‘adjuvant’’ setting using the
chondrosarcoma model after intralesional curettage: everolimus
(1 mg/kg) or doxorubicin (1 mg/kg) treatment was initiated the
day after surgery and rats were followed until tumors reached an
approximate diameter of 2 cm, at which time the animals were
sacrificed (Figure 5). For these conditions, data presented are one
experiment representative of the two experiments conducted.
Local regrowth was not abolished in everolimus-treated animals
but it occurred significantly later in comparison to control and
doxorubicin treated animals. At all time points, the mean tumor
volume was significantly smaller for everolimus treated animals
than in the control and doxorubicin treated groups (Figure S2). At
day 14 when all animals were still alive, the mean tumor volume
was 3400 mm
3 (+/2370), 2950 mm
3 (+/2340) and 900 mm
3 (+/
2300) respectively in the control, doxorubicin and everolimus
treated groups (Figure 5A and Figure 5B). In this setting
doxorubicin did not cause a delay in tumor regrowth; the
difference observed between the control rats and the doxorubicin
treated rats was not significant (p=0.052) while everolimus
induced a dramatic slowdown of tumor progression. Progression
between day 1 and 17 was significantly higher in control and
doxorubicin treated groups than for the animals receiving
everolimus (p=0.004 and p=0.01 respectively for the comparison
of control and everolimus treated groups and for the comparison
of doxorubicin and everolimus treated groups, Figure 5A). Using
Kaplan-Meier plots, everolimus significantly delayed the time for
tumors to reach a 2 cm diameter (P,0.001) (Figure 5B). In the
everolimus treated group, 50% of the animals did not reach this
critical size 40 days after surgery at which point the animals were
sacrificed, whereas in the doxorubicin and control groups all the
animals had reached this volume as early as day 18 (Figure 5A and
Figure S2). Ki67 and Glut-1 immunohistological analyses showed
a high decrease in Ki67+ cells and Glut-1 expression in the
everolimus treated tumors in comparison to the control and
doxorubicin treated tumors (data not shown).
Discussion
In this work, we demonstrate the therapeutic role of mTOR
inhibition in chondrosarcoma in localized and advanced phase.
Everolimus was tested in an orthotopic rat grade II chondrosar-
coma model in macroscopic and ‘‘adjuvant’’ phase both reaching
the same conclusion. As a single agent, the mTOR inhibitor
everolimus did not cause tumor regression but induced a
significant inhibition of tumor growth. Both the size and tumor
growth rate were smaller in the everolimus treated groups than in
other groups, as observed in other tumor models [13,18,19,21,22].
Doxorubicin was inactive as single agent; when combined with
everolimus, an antagonistic effect was actually observed in the
combination group compared to the everolimus treated group.
When compared to doxorubicin alone, the combination treatment
showed however an increased therapeutic efficiency. Although
these data are strongly contrasting with those observed in breast
cancer models with paclitaxel and prostate cancer with doxoru-
bicin [23,24], a similar effect was recently reported. In human
cervical carcinoma xenograft models the addition of everolimus to
doxorubicin showed an antitumor effect that was not significantly
different from doxorubicin monotherapy [25].
The mechanisms underlying this lack of synergism between the
two drugs are unclear. One of the side effects of doxorubicin
treatment is the induction of reactive oxygen species which in turn
can activate the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR
pathways [26–29]. This activation of the mTOR/Akt pathway
induced by doxorubicin is reflected by slight increase in Akt
phosphorylation in the doxorubicin treated group of our study. In
the case of combined treatment this doxorubicin-induced Akt
phosphorylation may not be overcome by everolimus at the
concentration used and may counteract the antitumor activity of
everolimus, as suggested by the higher expression of phospho Akt
of the combination group compared to the everolimus-treated one.
In the chondrosarcoma model the activity of the mTOR
pathway in response to the different treatments was monitored by
following activation levels of 4EBP1, S6K as potential surrogate
markers of tumor response. Measurement of the phosphorylation
status of ph-p70S6K1 and ph-4EBP1 in the tumor itself,
confirmed that everolimus resulted in a downregulation of mTOR
downstream effectors, whereas doxorubicin had no effect on its
phosphorylation status. Everolimus exposure alone did not result
in the activation of Akt, a phenomenon already reported in other
studies [30–32]. It is known that mTOR inhibitor– can induce a
feedback activation of Akt thus contributing to a lesser therapeutic
efficiency [32]. This was not observed here with everolimus alone.
The data obtained in these experiments indicate that everolimus
may affect cell proliferation and metabolism as shown by the down
regulation of Ki67 and Glut1 immunostaining. Such an antipro-
liferative effect has already been reported [12]. The significantly
decreased GLUT1 expression observed in the everolimus treated
groups appears to be the result of mTOR inhibition and is a
consequence of the cross-talk of mTOR downstream effectors with
metabolic and hypoxic pathways [33]. Inhibition of mTOR
signaling may have direct effect on cell proliferation and also an
indirect inhibitor effect on glucose metabolism through the
inhibition of HIF1a which expression is dependent upon mTOR
[6,33]. The decrease in HIF1a expression seen by immunofluo-
rescence and in the levels of HIF1 a transcript seen by RT-qPCR
in tumors of the everolimus treated groups support this
bifunctional action of everolimus.
Importantly, the present study also investigated the effects of
everolimus on residual disease after intralesional curettage in the
rat model of chondrosarcoma. In contrast to doxorubicin which
was unable to inhibit chondrosarcoma regrowth, everolimus
treatment significantly delayed local recurrence in the treated
group but did not prevent it after intralesional curettage. The
preclinical model used in this study reproduces thus clinical
situations in large chondrosarcoma. This suggests that everolimus
could be worth exploring as adjuvant treatment at least in patients
with grade 2 or higher chondrosarcoma. Whether everolimus
would be able to show the same antitumor activity in all
chondrosarcoma subtypes will be tested in a prospective random-
ized trial scheduled to be activated in 2012 in the French Sarcoma
Group.
Although everolimusasmonotherapyshowed astrong antitumor
effect and did not induce an increase in phosphorilated Akt in our
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e32458chondrosarcoma model one cannot put aside the possibility that
resistance could emerge in response to long term mTORC1
inhibition.ItisknownthatblockadeofmTORsignalingbyrapalogs
leads to loss of feedback inhibition on Akt [34]. That could
potentially result in increased cell survival and resistance to cancer
therapy [35]. To prevent such resistance mechanism and addition-
ally improve everolimus therapeutic efficiency everolimus-based
combination therapy could be envisionned. Such dual targeted
approaches targeting mTOR and Akt [36], or mTOR and PI3K
have proven to be pertinent in preclinical models [34] and one
(targeting mTOR and IGFR-1) has reached the clinical phase in
patients with advanced sarcomas and other solid tumors [35].
Another possible combination could be to add a bone
remodelling agent to everolimus.
Indeed, the combination of zoledronate to everolimus was
effective in inhibiting tumor progression and in protecting bone in
murine osteosarcoma model [37]. The latter effect being the result
of zoledronate rather than the one of everolimus. Like osteosar-
coma, chondrosarcoma is characterized by a tumor-induced
osteolysis; moreover, zoledronate has already proven to be an
efficient agent in the same chondrosarcoma model [38]. Thus it
seems pertinent to hypothesize that the combination of everolimus
to zoledronate could be efficient in this tumor. Such combined
therapies are worth exploring in preclinical settings.
In conclusion, the present results show that everolimus would be
an effective antitumor agent in chondrosarcoma. Besides, the
inhibition of tumor regrowth following surgery suggests that
everolimus could be used as adjuvant long-term therapy in
chondrosarcoma patients following surgery. These results open the
way to new therapeutic approaches and led to a prospective phase
II clinical trial initiatied in the French Sarcoma Group.
Supporting Information
Figure S1 Effects of everolimus and doxorubicin on
sarcoma cell proliferation in vitro. Chondrosarcoma (A)
and osteosarcoma (B) cells were incubated with increasing
concentration of everolimus and doxorubicin. Growth inhibition
was analyzed from T0 to T0+96 hrs, using the cell titer glo assay.
Absorbance values were normalized to 100% using the values
from untreated cells. Results are the mean 6 SD of three
independent experiments.
(TIF)
Figure S2 Individual progression of tumor volume after
intralesional curetage and corresponding treatment. All
tumors from the control and doxorubicin treated groups reached
the limit size of 2 cm in less than 20 days after curettage. A slower
progression was obtained Under Everolimus treatment.
(TIF)
Acknowledgments
We thank JB Langlois at the Animage imaging platform for help and
excellent care of the animals, the ‘‘Ligue Contre le Cancer’’ (comite ´d el a
Dro ˆme), NETSARC, RREPS, LYRIC, CONTICANET, EUROSARC
(European Union Seventh Framework Programme (FP7/2007–2013)
under Grant Agreement nu27874 ) for their financial support.
Author Contributions
Conceived and designed the experiments: AD JYB. Performed the
experiments: JP TP AD DP JPM. Analyzed the data: JP AD AVD.
Contributed reagents/materials/analysis tools: AB AVD DP. Wrote the
paper: AD JYB JP.
References
1. Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, et al.
(2008) The clinical approach towards chondrosarcoma. Oncologist 13: 320–329.
2. Dickey ID, Rose PS, Fuchs B, Wold LE, Okuno SH, et al. (2004)
Dedifferentiated chondrosarcoma: the role of chemotherapy with updated
outcomes. J Bone Joint Surg Am 86-A: 2412–2418.
3. Kalinski T, Sel S, Kouznetsova I, Ropke M, Roessner A (2009) Heterogeneity of
angiogenesis and blood vessel maturation in cartilage tumors. Pathol Res Pract
205: 339–345.
4. Bovee JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC (2005) Emerging
pathways in the development of chondrosarcoma of bone and implications for
targeted treatment. Lancet Oncol 6: 599–607.
5. Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN (2009) The role of
mTOR in the management of solid tumors: an overview. Cancer Treat Rev 35:
148–159.
6. Yuan R, Kay A, Berg WJ, Lebwohl D (2009) Targeting tumorigenesis:
development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol
2: 45.
7. Fingar DC, Blenis J (2004) Target of rapamycin (TOR): an integrator of nutrient
and growth factor signals and coordinator of cell growth and cell cycle
progression. Oncogene 23: 3151–3171.
8. Inoki K, Ouyang H, Li Y, Guan KL (2005) Signaling by target of rapamycin
proteins in cell growth control. Microbiol Mol Biol Rev 69: 79–100.
9. Wan X, Helman LJ (2007) The biology behind mTOR inhibition in sarcoma.
Oncologist 12: 1007–1018.
10. Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, et al.
(2007) The AKT-mTOR pathway plays a critical role in the development of
leiomyosarcomas. Nat Med 13: 748–753.
11. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR
inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671–688.
12. Ito D, Fujimoto K, Mori T, Kami K, Koizumi M, et al. (2006) In vivo antitumor
effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of
human pancreatic cancer. Int J Cancer 118: 2337–2343.
13. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, et al. (2007)
RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse
model of ovarian cancer. Cancer Res 67: 2408–2413.
14. Nathan CO, Amirghahari N, Rong X, Giordano T, Sibley D, et al. (2007)
Mammalian target of rapamycin inhibitors as possible adjuvant therapy for
microscopic residual disease in head and neck squamous cell cancer. Cancer Res
67: 2160–2168.
15. Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, et al. (2009) A phase I
study of the mammalian target of rapamycin inhibitor sirolimus and MEC
chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin
Cancer Res 15: 6732–6739.
16. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, et al.
(2010) Clinical activity of mTOR inhibition with sirolimus in malignant
perivascular epithelioid cell tumors: targeting the pathogenic activation of
mTORC1 in tumors. J Clin Oncol 28: 835–840.
17. Merimsky O, Bernstein-Molho R, Sagi-Eisenberg R (2008) Targeting the
mammalian target of rapamycin in myxoid chondrosarcoma. Anticancer Drugs
19: 1019–1021.
18. Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, et al. (2008) Inhibition of
mTOR pathway by everolimus cooperates with EGFR inhibitors in human
tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 98: 923–930.
19. Piguet AC, Semela D, Keogh A, Wilkens L, Stroka D, et al. (2008) Inhibition of
mTOR in combination with doxorubicin in an experimental model of
hepatocellular carcinoma. J Hepatol 49: 78–87.
20. Gouin F, Ory B, Redini F, Heymann D (2006) Zoledronic acid slows down rat
primary chondrosarcoma development, recurrent tumor progression after
intralesional curretage and increases overall survival. Int J Cancer 119: 980–984.
Figure 5. Everolimus as adjuvant treatment delayed chondrosarcoma relapse. A: graph showing mean tumor growth in each group
between day 1 and day 14 after surgery. A significant difference in tumor progression was observed between the everolimus treated group and the
other groups. B: Longitudinal growth of tumor of one rat from each group monitored by MRI. C: Kaplan Meyer curve and statistical analysis of control
and drug-treated groups showing the probability for animals of being event-free (i.e. for tumors to reach 2 cm in diameter). The statistical analyses
indicate a significant benefit of everolimus treatment to delay chondrosarcoma progression (P,0.01) over control and doxorubicin. RMTV: relative
mean tumor volume as compared to day 1 initiation of treatment.
doi:10.1371/journal.pone.0032458.g005
Inhibition of Chondrosarcoma Progression by RAD001
PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e32458
221. Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, et al. (2009) Targeted inhibition of
mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal
cancer. Clin Cancer Res 15: 7207–7216.
22. Zhang W, Zhu J, Efferson CL, Ware C, Tammam J, et al. (2009) Inhibition of
tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-
deficient mouse model of prostate cancer. Cancer Res 69: 7466–7472.
23. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, et al. (2004) Targeting
mammalian target of rapamycin synergistically enhances chemotherapy-induced
cytotoxicity in breast cancer cells. Clin Cancer Res 10: 7031–7042.
24. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, et al. (2002)
Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in
prostate cancer cells. Cancer Res 62: 6141–6145.
25. O’Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, et al. (2011)
Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic
antitumor agents using human tumor models in vitro and in vivo. Anticancer
Drugs 22: 58–78. 10.1097/CAD.0b013e3283400a20 [doi].
26. Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, et al. (2010)
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and
sensitivity to targeted therapy. Cell Cycle 9: 1781–1791.
27. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, et al. (2008)
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK,
PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia
therapy. Leukemia 22: 708–722.
28. McCubrey JA, Sokolosky ML, Lehmann BD, Taylor JR, Navolanic PM, et al.
(2008) Alteration of Akt activity increases chemotherapeutic drug and hormonal
resistance in breast cancer yet confers an achilles heel by sensitization to targeted
therapy. Adv Enzyme Regul 48: 113–135.
29. Shelton JG, Steelman LS, White ER, McCubrey JA (2004) Synergy between
PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle
progression and prevention of apoptosis in hematopoietic cells. Cell Cycle 3:
372–379.
30. O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. (2006) mTOR inhibition
induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer
Res 66: 1500–1508.
31. Tremblay F, Marette A (2001) Amino acid and insulin signaling via the mTOR/
p70 S6 kinase pathway. A negative feedback mechanism leading to insulin
resistance in skeletal muscle cells. J Biol Chem 276: 38052–38060.
32. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces
feedback activation of Akt signaling through an IGF-1R-dependent mechanism.
Oncogene 26: 1932–1940.
33. Wouters BG, Koritzinsky M (2008) Hypoxia signalling through mTOR and the
unfolded protein response in cancer. Nat Rev Cancer 8: 851–864.
34. Mazzoletti M, Bortolin F, Brunelli L, Pastorelli R, Di GS, et al. (2011)
Combination of PI3K/mTOR inhibitors: antitumor activity and molecular
correlates. Cancer Res 71: 4573–4584. 0008–5472.CAN-10–4322
[pii];10.1158/0008–5472.CAN-10–4322 [doi].
35. Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, et al. (2011)
Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and
figitumumab in patients with advanced sarcomas and other solid tumors. Clin
Cancer Res 17: 871–879. 1078–0432.CCR-10–2621 [pii];10.1158/1078-
0432.CCR-10–2621 [doi].
36. Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara DR, et al. (2011)
Evaluating rational non-cross-resistant combination therapy in advanced clear
cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer
Chemother Pharmacol. 10.1007/s00280–011–1684-y [doi].
37. Moriceau G, Ory B, Mitrofan L, Riganti C, Blanchard F, et al. (2010)
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of
osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation
process. Cancer Res 70: 10329–10339. 0008–5472.CAN-10–0578
[pii];10.1158/0008-5472.CAN-10-0578 [doi].
38. Gouin F, Ory B, Redini F, Heymann D (2006) Zoledronic acid slows down rat
primary chondrosarcoma development, recurrent tumor progression after
intralesional curretage and increases overall survival. Int J Cancer 119: 980–
984. 10.1002/ijc.21951 [doi].
Inhibition of Chondrosarcoma Progression by RAD001
PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e32458